Info
clinical_decision-making_and_treatment_of_myelodysplastic_syndromes
Hellström-Lindberg ES, Kröger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142(26):2268-2281. doi:10.1182/blood.2023020079
Patient assessment and goal of treatment
- TD (transfusion dependency): 50% need RBC transfusion
- Initial decision-making
- Supportive care
- Iron chelation therapy
- Criteria for response to treatment
- Growth factor treatment
- Luspatercept
- Immunosuppressive treatment
- Lenalidomide treatment
- Imetelstat and other novel targeted drugs for lower-risk MDS
- Hypomethylating agents
- HMA in combination with novel agents and molecularly targeted drugs
- Chemotherapy
- Stem cell transplantation
